Text

Low Dose Hydroxyurea or Ara-C with Alpha-2 Combined with Beta Interferon in Chronic Leukemia Granulositic : A Multicenter Research (Kombinasi Hidroksiurea atau Ara-C Dosis Rendah dengan Alfa - 2 Beta Interferon pada Lekemi Granulositik Kronik : Suatu Penelitian Multisenter)

---

A multicenter, clinical trial, randomized open label and parallel study has been done since April 1993 on the Chronic Myelogenous Leukemia patients treated with either Interferon (I) + Hydroxyurea (HU) or Interferon + low dose Ara-C (C). The countries who involve on this study are Indonesia, China, India, Philippines, Singapore, South Korea and Taiwan. The dose of Interferon is 5 MU 5 days a week, HU 55 mg/kg body weight 5 days a week and Ara-C 15 mg subcutan 5 days a week. The objectives of these study are to compare and contrast the episode of blast crisis, survival, hematological and cytogenetic remission, 39 patients enrolled this study, 33 HI and 6 CI. Dropped out patient was 4 HI group 2 in CI group, 1 more patient in GI group dropped-out during maintenance therapy. Those who still alive are 3 in HI and 2 in CI. The reason for dropping out was misdiagnosis, last to follow up, economic hardship or had bone marrow transplant. There is 1 biologic remission in HI group. All patients on maintenance therapy are alive after a median of 8 months of therapy analysis will be done after 200 patients, 100 for each arm.

---

Availability

Detail Information

Series Title

-

Call Number

Majalah Kedokteran Bandung,27(3)1995:83-87

Publisher

: ., 1995

Collation

-

Language

ISBN/ISSN

-

Classification

-

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

hydroxyurea
interferon alfa-2b
leukemia, myeloid, chronic

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment